Avian polyomavirus vaccine in psittacine birds

Details Avian polyomavirus vaccine in psittacine birds Avian polyomavirus vaccine in psittacine birds

1996-06-03

1998-05-05

Knode, Marian C.

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

4242791, 4242821, 4242801, 435 691, 435 701, 435 711, A61K 3912, C12P 2106

Patent

active

057470456

ABSTRACT:
The present invention provides a vaccine which is protective against avian polyomavirus infection in a bird which is classified as being a member of the Psittaciformes order which comprises an immunogenic amount of an inactivated avian polyomavirus in a pharmaceutically acceptable carrier. Also provided is a vaccine which is protective against avian polyomavirus infection in a bird which is classified as being a member of the Psittaciformes order, comprising an immunogenic amount of a recombinant protein derived from an avian polyomavirus and a pharmaceutically acceptable carrier. Also provided is an adjuvant suitable for use in a bird which is classified as being a member of the Psittaciformes order. Further provided is a composition which produces an anamnestic response against avian polyomavirus infection in a sensitized bird which is classified as being a member of the Psittaciformes order, which comprises an anamnestic response inducing amount of a recombinant protein (e.g., VP1 capsid protein) of avian polyomavirus in a pharmaceutically acceptable carrier. Methods are also provided for preventing avian polyomavirus infection in a bird, or in several different species of birds, classified as being a member of the Psittaciformes order, comprising administering a vaccine comprising an immunogenic amount of a inactivated avian polyomavirus and a pharmaceutically acceptable carrier.

REFERENCES:
Griffiths, E. "Assuring the Quality of Vaccines" Edited by Robinson et al in Methods of Molecular Medicine:Vaccine Protocols. New Jersey, Humana Press, pp. 269-288, 1996.
Niikura et al. "Expression of the Marek's Disease Virus (MDV) Homolog of Glycoprotein B of Herpes Simplex Virus by a Recombinant Baculovirus and Its Identification as the B Antigen (gp 100,gp60,gp49) of MDV", Journal of Virology, vol. 66, No. 5, pp. 2631-2638, 1992.
Gaskin, J.M. "Adverse Reactions to Current Pet Bird Vaccines". IAAV. vol. 5, No. 1, pp. 12-14, 1991.
Chinnah et al. "Antigen dependent adjuvant activity of polydispersed B-(1,4)-linked acetylated mannan (acemannan)". Vaccine. vol. 10, Iss.8, pp. 551-557, 1992.
Ellis, R.W. "New Technologies for Making Vaccines". Edited by Plotkin et al in Vaccines, Chapter 29. W.B.Saunders Company. pp. 568-575, 1988.
Dahlhausen et al. "Update on Psittacine Beak and Feather Disease and Avian Polyomavirus". from the 1993 Annual Conference of th Association of Avian Veterinarians, Aug. 31-Sep. 4 in Nashville, Tennessee. pp. 5-7. 1993.
Stoll et al. "Molecular and biological characteristics of avian polyomaviruses:isolates from different species of birds indicate that avian polyomaviruses from a distinct organisms within the polyomavirus genus". Journal of General Virology. vol. 74, p. 22, 1993.
Rott et al. "The Genome of Budgerigar Fleddging Disease Virus, an Avian Polyomavirus". Virology. vol. 165, pp. 74-86, 1988.
Gay et al. "Confirming the Safety Characteristics of Recombinant Vectors Used in Veterinary medicine: A Regulatory Perspective". Edited by Brown et al, in Recombinant Vectors in Vaccine Development. Basel, Karger. vol. 82, pp. 93-105, 1994.

Affiliated with

Also associated with

Rating

Avian polyomavirus vaccine in psittacine birds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Avian polyomavirus vaccine in psittacine birds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Avian polyomavirus vaccine in psittacine birds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-51173